Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An affinity-enhanced, broadly neutralizing heavy chain–only antibody protects against SARS-CoV-2 infection in animal models
Bert Schepens, Loes van Schie, Wim Nerinckx, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 621
Open Access | Times Cited: 55

Showing 1-25 of 55 citing articles:

A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo
Leo Hanke, Hrishikesh Das, Daniel J. Sheward, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 73
Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses
Mingxi Li, Yifei Ren, Zhen Qin Aw, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 55
Impaired immune response drives age-dependent severity of COVID-19
Julius Beer, Stefania Crotta, Angele Breithaupt, et al.
The Journal of Experimental Medicine (2022) Vol. 219, Iss. 12
Open Access | Times Cited: 42
Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses
Yang Yang, Fang Li, Lanying Du
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 9
Nanoscale warriors against viral invaders: a comprehensive review of Nanobodies as potential antiviral therapeutics
Vaishali Verma, N. D. Sinha, A. Raja
mAbs (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 1
Gold Nanoparticle-Mediated Lateral Flow Assays for Detection of Host Antibodies and COVID-19 Proteins
Leila Safaee Ardekani, Peter W. Thulstrup
Nanomaterials (2022) Vol. 12, Iss. 9, pp. 1456-1456
Open Access | Times Cited: 34
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
William R. Strohl, Zhiqiang Ku, Zhiqiang An, et al.
BioDrugs (2022) Vol. 36, Iss. 3, pp. 231-323
Open Access | Times Cited: 32
Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralizing SARS-CoV-2 nanobodies
Leo Hanke, Daniel J. Sheward, Alec Pankow, et al.
Science Advances (2022) Vol. 8, Iss. 12
Open Access | Times Cited: 29
Adaptive multi-epitope targeting and avidity-enhanced nanobody platform for ultrapotent, durable antiviral therapy
Yufei Xiang, Jialu Xu, Briana L. McGovern, et al.
Cell (2024)
Closed Access | Times Cited: 7
Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster models
Martín A. Rossotti, Henk van Faassen, Anh Tran, et al.
Communications Biology (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 27
SARS-CoV-2 Specific Nanobodies Neutralize Different Variants of Concern and Reduce Virus Load in the Brain of h-ACE2 Transgenic Mice
María F. Pavan, Marina Bok, Rafael Betanzos San Juan, et al.
Viruses (2024) Vol. 16, Iss. 2, pp. 185-185
Open Access | Times Cited: 5
Antibody drugs targeting SARS-CoV-2: Time for a rethink?
Likeng Liang, Bo Wang, Qing Zhang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 176, pp. 116900-116900
Open Access | Times Cited: 5
Anti-HIV-1 Nanobody-IgG1 Constructs With Improved Neutralization Potency and the Ability to Mediate Fc Effector Functions
Angela I. Schriek, Marlies M. van Haaren, Meliawati Poniman, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 20
Integrating artificial intelligence-based epitope prediction in a SARS-CoV-2 antibody discovery pipeline: caution is warranted
Delphine D. Acar, Wojciech Witkowski, Magdalena Wejda, et al.
EBioMedicine (2024) Vol. 100, pp. 104960-104960
Open Access | Times Cited: 4
Anti-SARS-CoV-1 and −2 nanobody engineering towards avidity-inspired therapeutics
Eugene M. Obeng, Christian K. O. Dzuvor, Michael K. Danquah
Nano Today (2021) Vol. 42, pp. 101350-101350
Open Access | Times Cited: 26
Biparatopic nanobodies protect mice from lethal challenge with SARS‐CoV‐2 variants of concern
Teresa R. Wagner, Daniel Schnepf, Julius Beer, et al.
EMBO Reports (2021) Vol. 23, Iss. 2
Open Access | Times Cited: 25
Structure-based dual affinity optimization of a SARS-CoV-1/2 cross-reactive single-domain antibody
Traian Sulea, Jason Baardsnes, Matthew Stuible, et al.
PLoS ONE (2022) Vol. 17, Iss. 3, pp. e0266250-e0266250
Open Access | Times Cited: 19
First-in-class trispecific VHH-Fc based antibody with potent prophylactic and therapeutic efficacy against SARS-CoV-2 and variants
Allison Titong, Sachith Gallolu Kankanamalage, Jianbo Dong, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 19
A Class of Shark‐Derived Single‐Domain Antibodies can Broadly Neutralize SARS‐Related Coronaviruses and the Structural Basis of Neutralization and Omicron Escape
Bo Feng, Zhilong Chen, Jing Sun, et al.
Small Methods (2022) Vol. 6, Iss. 7
Open Access | Times Cited: 19
Unlocking the potential of in silico approach in designing antibodies against SARS-CoV-2
Tasshitra R. Subramaniam, Siti Aisyah Mualif, Weng Howe Chan, et al.
Frontiers in Bioinformatics (2025) Vol. 5
Open Access
Identification and characterization of a broadly neutralizing and protective nanobody against the HA1 domain of H5 avian influenza virus hemagglutinin
Siqi Xu, Y. H. Liu, C. L. Luo, et al.
Journal of Virology (2025)
Open Access
Characterization of Nanobody Binding to Distinct Regions of the SARS-CoV-2 Spike Protein by Flow Virometry
Mariam Maltseva, Martín A. Rossotti, Jamshid Tanha, et al.
Viruses (2025) Vol. 17, Iss. 4, pp. 571-571
Open Access
Promises and challenges of single-domain antibodies to control influenza
Arne Matthys, Xavier Saelens
Antiviral Research (2024) Vol. 222, pp. 105807-105807
Closed Access | Times Cited: 3
Deep mutational engineering of broadly-neutralizing nanobodies accommodating SARS-CoV-1 and 2 antigenic drift
Adrien Laroche, María Lucía Orsini Delgado, Benjamin Chalopin, et al.
mAbs (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 13
Nanobodies: COVID-19 and Future Perspectives
G Valenzuela, Zaray Miranda-Chacón, Constanza Salinas-Rebolledo, et al.
Frontiers in Drug Discovery (2022) Vol. 2
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top